TransMedics Group (NASDAQ:TMDX) Shares Up 6.6% – What’s Next?

TransMedics Group, Inc. (NASDAQ:TMDX)’s stock price rose 6.6% on Tuesday . The stock traded as high as $64.80 and last traded at $65.10. Approximately 473,159 shares were traded during trading, a decline of 84% from the average daily volume of 2,965,165 shares. The stock had previously closed at $61.07.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on TMDX shares. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research note on Wednesday, December 11th. Canaccord Genuity Group reduced their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. TD Cowen lowered their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a research report on Tuesday, December 3rd. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Price Performance

The business has a 50-day moving average price of $68.25 and a two-hundred day moving average price of $113.99. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of 71.31 and a beta of 2.12.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). The business had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business’s quarterly revenue was up 63.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.12) EPS. As a group, research analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Buying and Selling

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. This trade represents a 4.94 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward M. Basile sold 6,750 shares of the stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the completion of the sale, the director now owns 732 shares of the company’s stock, valued at approximately $61,158.60. This represents a 90.22 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TransMedics Group

A number of hedge funds have recently made changes to their positions in the business. Hager Investment Management Services LLC purchased a new stake in TransMedics Group during the fourth quarter worth about $33,000. Sachetta LLC bought a new position in shares of TransMedics Group during the 4th quarter valued at approximately $40,000. USA Financial Formulas purchased a new stake in shares of TransMedics Group during the 3rd quarter worth approximately $55,000. Quarry LP increased its stake in shares of TransMedics Group by 557.1% during the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after purchasing an additional 312 shares during the last quarter. Finally, National Bank of Canada FI raised its holdings in shares of TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after purchasing an additional 262 shares during the period. 99.67% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.